Akebia Therapeutics Cash Flow - Quarterly (NASDAQ:AKBA)

Add to My Stocks
$8.33 $0.59 (7.62%) AKBA stock closing price Sep 20, 2018 (Closing)

The Akebia Therapeutics cash flow statement helps investors understand how well the company is managing its cash flows. While its important to look at the Akebia Therapeutics debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as Akebia Therapeutics revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. Akebia Therapeutics stock analysis shows negative net income cash flow of $-57.49M till 2018 Q2. This statement is important because profits alone cannot pay employees, or bills. Cash is required. The cash from operating activities for Akebia Therapeutics is $ 2018 Q2, which saw an increase from previous quarter.

View and download details of Akebia Therapeutics cash flows for latest & last 40 quarters
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
-57.49M-23.41M-76.91M-89.19M-66.06M-44.54M-135.74M-97.88M-61.57M-25.79M
Depreciation Depletion Amortization Cash-Flow--1.22M-------
Net Increase (Decrease) in Assets Liabilities41.33M-7.24M38.36M72.31M29.26M186.73M55.14M49.21M41.8M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net4.73M2.23M12.28M10.08M7.93M5.42M6.13M4.4M2.47M1.25M
Net Cash from (used by) Operating Activities
-11.33M-20.33M-56.15M-39.78M14.83M-9.52M57.9M-37.76M-9.52M17.43M
Increase (Decrease) in Prop Plant And Equipment-0.47M-0.29M-1.62M-1.17M-0.57M-0.42M-2.66M-2.61M-1.35M-0.1M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments9.33M12.73M-175.63M-167.78M-123.41M-91.87M15.36M-6.98M-53.81M-84.84M
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
8.87M12.43M-177.26M-168.95M-123.99M-92.3M12.7M-9.6M-55.16M-84.95M
Issuance (Purchase) of Equity Shares96.13M95.91M116.24M111M47.21M1.74M66.96M63.43M61.09M61.18M
Issuance (Repayment) of Debt Securities-0.01M--0.01M----0.02M-0.01M-0.01M-
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
96.12M95.91M116.24M110.99M47.21M1.74M66.94M63.41M61.08M61.18M
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
93.66M88.01M-117.17M-97.73M-61.94M-100.08M137.55M16.05M-3.6M-6.33M
Cash & Equivalents at Beginning of Year71.44M187.33M49.77M32.78M21.21M1.64M5.01M---
Cash & Equivalents at Year End165.09M159.45M70.15M89.59M125.39M87.25M187.33M65.83M46.17M43.43M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Akebia Therapeutics stock price history and Akebia Therapeutics stock comparison chart inevitably reflect its cash flow situation.

  • Akebia Therapeutics had a Net Change in Cash and Cash Equivalents of $93.66M in the latest quarter 2018 Q2. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Akebia Therapeutics stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Akebia Therapeutics decreased its cash from operating activities to $-11.33M till 2018 Q2. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: Akebia Therapeutics generated $8.87M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $96.12M for Akebia Therapeutics. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Akebia Therapeutics Cash Flow

FCF margin
0.18